Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions to Participate in Upcoming Investor Conferences GlobeNewswire May 14, 2025 GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New York)Fireside chat on Tuesday, May 20 at […]

Introduction to UXUY Protocol

Introduction to UXUY Protocol GasLess Transactions Are Significantly Lowering the Barrier to On-Chain Trading GlobeNewswire May 14, 2025 Singapore, May 14, 2025 (GLOBE NEWSWIRE) — AbstractThe advent of crypto has created the largest ownerless asset system in human history. Under the guidance of evolving crypto narratives, assets are being minted, issued, traded, and stored at

NetReputation.com Reports Record Year-Over-Year Growth, Projects Major Global Expansion

SARASOTA, Fla., May 14, 2025 (GLOBE NEWSWIRE) — NetReputation.com, a leading innovator in online reputation management, today announced a record-breaking year in 2024, achieving over $19 million in gross revenue, marking a 30% year-over-year increase from $15 million in 2023. The company's continued growth highlights its expanding market share and dominant presence in the digital

Bombardier Announces Launch of US$500 million New Issuance of Senior Notes due 2033 to retire US$500 million of its Senior Notes due 2027

(TSX:BBD-A),(TSX:BBD-B),(OTC US:BDRBF),(Other OTC:BDRBF), MONTRÉAL, May 14, 2025 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has launched an offering of US$500 million aggregate principal amount of new Senior Notes due 2033 (the “New Notes”). Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i)

Pony AI Inc. Announces Voluntary Extended Lock-Ups by Founders

(NASDAQ:PONY), SHANGHAI, China, May 14, 2025 (GLOBE NEWSWIRE) — Pony AI Inc. (“Pony.ai” or the “Company”) (Nasdaq: PONY), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that Dr. Jun Peng, Chairman of the Board, Co-founder, and CEO, and Dr. Tiancheng Lou, Co-founder and CTO, have each entered into voluntary extended lock-up

[Latest] Global Pharmaceutical Container Market Size/Share Worth USD 189.45 Billion by 2034 at a 6.98% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, May 14, 2025 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled “Pharmaceutical Container Market Size, Trends and Insights By Product Type (Bottles, Vials & Ampoules, Bags & Pouches, Prefilled Syringes & Cartridges, Trays, Tubes), By Material Type (Plastics, Glass, Metal), and By Region – Global Industry Overview,

NetReputation.com Reports Record Year-Over-Year Growth, Projects Major Global Expansion

NetReputation.com Reports Record Year-Over-Year Growth, Projects Major Global Expansion GlobeNewswire May 14, 2025 SARASOTA, Fla., May 14, 2025 (GLOBE NEWSWIRE) — NetReputation.com, a leading innovator in online reputation management, today announced a record-breaking year in 2024, achieving over $19 million in gross revenue, marking a 30% year-over-year increase from $15 million in 2023. The company's

Erdene Announces Q1 2025 Results and Provides Bayan Khundii Project Update

(TSX:ERD), HALIFAX, Nova Scotia, May 14, 2025 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce operating and financial results for the quarter ended March 31, 2025, and to provide an update on progress at the Bayan Khundii Gold Project (“BK” or “Project”), being developed with Mongolian

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

(NASDAQ:INZY), – Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date – – ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

(NASDAQ:ABUS), Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion

Scroll to Top